-1 #(S1 (S (NP (NP (DT The) (JJ relative) (NNS risks)) (PP (IN between) (NP (NP (JJS highest) (CC and) (JJS lowest) (NNS quarters)) (PP (IN of) (NP (NP (NN _PROT1_) (NN intake)) (VP (VBN adjusted) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NN smoking)) (, ,) (NP (NN serum) (NN _PROT2_) (NN concentration)) (, ,) (NP (NN blood) (NN pressure)) (, ,) (CC and) (NP (NN body) (NN mass) (NN index)))))))))) (VP (VBD were) (NP (NP (NP (CD 0.69)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN confidence) (NN interval) (CD 0.53) (TO to) (CD 0.90)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 0.54)) (PRN (-LRB- -LRB-) (NP (CD 0.33) (TO to) (CD 0.87)) (-RRB- -RRB-)))) (PP (IN for) (NP (ADJP (ADJP (JJ total)) (CC and) (ADJP (JJ coronary))) (NN mortality))) (, ,) (ADVP (RB respectively)))))
+1 #(S1 (S (NP (NP (NP (NN Correlation)) (PP (IN between) (NP (NP (DT the) (JJ stimulatory) (NN effect)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN on) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ _PROT2_) (NNS _PROT2_)))))))) (CC and) (NP (NP (DT the) (NN oxytocin) (NN receptor) (NN level)) (PP (IN in) (NP (DT the) (JJ pregnant) (NN rabbit) (NN myometrium)))))))
-1 #(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NNS roles)) (PP (IN of) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (CC and) (NP (NP (NN oxytocin)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-)))) (NNS receptors))) (PP (IN in) (NP (NN rabbit) (NN parturition)))))))) (, ,) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NN _PROT2_)) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT_)) (CC and) (NP (DT the) (NN OT) (NN receptor)) (NP (NNS levels)))))))) (VP (VBD were) (VP (VBN determined) (PP (IN in) (NP (NN rabbit) (NNS myometria))) (PP (PP (IN before)) (CC and) (PP (IN after) (NP (NN parturition))))))))))
-1 #(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NNS roles)) (PP (IN of) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (CC and) (NP (NP (NN oxytocin)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-)))) (NNS receptors))) (PP (IN in) (NP (NN rabbit) (NN parturition)))))))) (, ,) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NN _PROT_)) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT2_)) (CC and) (NP (DT the) (NN OT) (NN receptor)) (NP (NNS levels)))))))) (VP (VBD were) (VP (VBN determined) (PP (IN in) (NP (NN rabbit) (NNS myometria))) (PP (PP (IN before)) (CC and) (PP (IN after) (NP (NN parturition))))))))))
+1 #(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NNS roles)) (PP (IN of) (NP (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (CC and) (NP (NP (NN oxytocin)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-)))) (NNS receptors))) (PP (IN in) (NP (NN rabbit) (NN parturition)))))))) (, ,) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NN _PROT1_)) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT2_)) (CC and) (NP (DT the) (NN OT) (NN receptor)) (NP (NNS levels)))))))) (VP (VBD were) (VP (VBN determined) (PP (IN in) (NP (NN rabbit) (NNS myometria))) (PP (PP (IN before)) (CC and) (PP (IN after) (NP (NN parturition))))))))))
-1 #(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN on) (NP (NP (NN _PROT2_) (NN formation)) (CC and) (NP (NN OT) (NN receptor) (NNS levels))))) (VP (VBD were) (VP (VBN determined) (PP (IN in) (NP (NP (DT the) (NNS myometria)) (PP (IN of) (NP (NP (JJ non-pregnant) (NNS rabbits)) (, ,) (NP (NP (NP (NNS Days) (CD 26)) (, ,) (NP (CD 28)) (CC and) (NP (CD 30))) (PP (IN of) (NP (NN pregnancy) (NNS rabbits)))) (, ,) (NP (NP (JJ postpartum) (NNS rabbits)) (PP (IN within) (NP (CD 12) (NNS hours)))) (CC and) (NP (JJ steroid-treated) (JJ ovariectomized) (NNS rabbits))))))))))))
+1 #(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (S (NP (NN OT) (NNS receptors)) (VP (VBD were) (RB not) (ADJP (JJ detectable) (PP (IN in) (NP (NP (DT the) (NNS myometria)) (PP (IN of) (NP (JJ non-pregnant) (NNS rabbits)))))))) (, ,) (CC and) (S (NP (NN _PROT1_)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (JJ _PROT2_) (NNS _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN IPs)) (-RRB- -RRB-))))))))))))
+1 #(S1 (S (PP (IN On) (NP (NP (NN Day) (CD 28)) (PP (IN of) (NP (NN pregnancy))))) (, ,) (S (S (NP (NN OT) (NNS receptors)) (VP (VBD became) (ADJP (JJ detectable)))) (, ,) (CC and) (S (ADVP (RB then)) (NP (NN _PROT1_)) (VP (MD could) (VP (VB induce) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NNS _PROT2_))))))))))
+1 #(S1 (S (ADVP (RB Thereafter)) (, ,) (NP (NP (NP (DT the) (JJ stimulatory) (NNS effects)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN on) (NP (NN _PROT2_) (NN formation)))) (CC and) (NP (DT the) (NN OT) (NN receptor) (NNS levels))) (ADVP (RB dramatically)) (VP (VP (VBD increased) (PP (IN toward) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN pregnancy)))))) (CC and) (VP (VBD reduced) (ADVP (RB rapidly)) (PP (IN after) (NP (NN parturition)))))))
+1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (JJ ovariectomized) (JJ pregnant) (NNS rabbits)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NN estrogen))))))) (, ,) (S (S (NP (NP (NN OT) (NNS receptors)) (PP (IN in) (NP (DT the) (NN myometrium)))) (VP (VBD were) (VP (VBN induced)))) (, ,) (CC and) (S (NP (NN _PROT1_)) (VP (VBD acquired) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB stimulate) (NP (NN _PROT2_) (NN formation)))))))))))
+1 #(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT an) (JJ OT) (NN receptor) (NN antagonist)) (VP (VBD inhibited) (NP (NP (DT the) (JJ stimulatory) (NNS effects)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN on) (NP (NN _PROT2_) (NN formation)))))))
+1 #(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN by) (NP (NP (NN _PROT2_)) (, ,) (NP (NP (DT the) (NN OT) (NN receptor) (NNS levels)) (PP (IN in) (NP (DT the) (NN myometrium)))) (, ,) (CC and) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NN PGF2))) (PP (IN in) (NP (DT the) (NN decidua))))))) (VP (MD might) (VP (VB play) (NP (JJ crucial) (NNS roles)) (PP (IN in) (NP (NN parturition))))))))))))
+1 #(S1 (S (NP (NN _PROT1_)) (VP (VP (VBZ upregulates) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN UCP-2)) (-RRB- -RRB-))) (NN mRNA))) (PP (IN in) (NP (NP (NNS islets)) (PP (IN of) (NP (JJ normal) (NNS rats))))))) (, ,) (CC but) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN in) (NP (NP (NNS islets)) (PP (IN of) (NP (JJ obese) (NN Zucker) (JJ Diabetic) (NN Fatty) (-LRB- -LRB-) (NN ZDF) (-RRB- -RRB-) (NNS rats))) (PP (IN with) (NP (VBN mutated) (NN leptin) (NNS receptors)))))))))
-1 #(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN 5-HT3) (JJ serotonergic) (NNS receptors))) (PP (IN with) (NP (NP (NN ondansetron)) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CC or) (CD 8)) (NN mg)) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB modify) (NP (NP (NP (DT the) (JJ basal) (NN secretion)) (PP (IN of) (NP (NP (NN AVP)) (CC and) (NP (NN _PROT1_))))) (CC and) (NP (NP (DT the) (JJ _PROT2_) (NN response)) (PP (TO to) (NP (JJ _PROT_) (NN hypoglycemia)))))))))
-1 #(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN 5-HT3) (JJ serotonergic) (NNS receptors))) (PP (IN with) (NP (NP (NN ondansetron)) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CC or) (CD 8)) (NN mg)) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB modify) (NP (NP (NP (DT the) (JJ basal) (NN secretion)) (PP (IN of) (NP (NP (NN AVP)) (CC and) (NP (NN _PROT1_))))) (CC and) (NP (NP (DT the) (JJ _PROT_) (NN response)) (PP (TO to) (NP (JJ _PROT2_) (NN hypoglycemia)))))))))
+1 #(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN 5-HT3) (JJ serotonergic) (NNS receptors))) (PP (IN with) (NP (NP (NN ondansetron)) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CC or) (CD 8)) (NN mg)) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB modify) (NP (NP (NP (DT the) (JJ basal) (NN secretion)) (PP (IN of) (NP (NP (NN AVP)) (CC and) (NP (NN _PROT_))))) (CC and) (NP (NP (DT the) (JJ _PROT1_) (NN response)) (PP (TO to) (NP (JJ _PROT2_) (NN hypoglycemia)))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB explore) (NP (NP (DT the) (JJ possible) (NNS roles)) (PP (IN of) (NP (DT the) (JJ hypothalamic) (NN melanocortin) (NN system))) (PP (IN in) (NP (NN _PROT1_) (NN action))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ intracerebroventricular)) (PRN (-LRB- -LRB-) (NP (NN i.c.v.)) (-RRB- -RRB-))) (NN injection)) (PP (IN of) (NP (NN _PROT2_))) (PP (IN with) (CC or) (PP (IN without) (NP (NP (NN SHU9119)) (, ,) (NP (NP (DT a) (JJ potent) (NN antagonist)) (PP (IN of) (NP (JJ alpha-melanocyte) (NN stimulating) (NN hormone)))) (, ,)))))) (PP (IN on) (NP (NP (NP (NN food) (NN intake)) (, ,) (NP (NN body) (NN weight)) (, ,) (CC and) (NP (NP (JJ mitochondrial) (VBG _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN UCP-1)) (-RRB- -RRB-))) (NP (NN mRNA) (NN expression))) (PP (IN in) (NP (NP (DT the) (JJ brown) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNS rats))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB explore) (NP (NP (DT the) (JJ possible) (NNS roles)) (PP (IN of) (NP (DT the) (JJ hypothalamic) (NN melanocortin) (NN system))) (PP (IN in) (NP (NN _PROT1_) (NN action))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ intracerebroventricular)) (PRN (-LRB- -LRB-) (NP (NN i.c.v.)) (-RRB- -RRB-))) (NN injection)) (PP (IN of) (NP (NN _PROT_))) (PP (IN with) (CC or) (PP (IN without) (NP (NP (NN SHU9119)) (, ,) (NP (NP (DT a) (JJ potent) (NN antagonist)) (PP (IN of) (NP (JJ alpha-melanocyte) (NN stimulating) (NN hormone)))) (, ,)))))) (PP (IN on) (NP (NP (NP (NN food) (NN intake)) (, ,) (NP (NN body) (NN weight)) (, ,) (CC and) (NP (NP (JJ mitochondrial) (VBG _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN UCP-1)) (-RRB- -RRB-))) (NP (NN mRNA) (NN expression))) (PP (IN in) (NP (NP (DT the) (JJ brown) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNS rats))))))))))
-1 #(S1 (S (S (VP (TO To) (VP (VB explore) (NP (NP (DT the) (JJ possible) (NNS roles)) (PP (IN of) (NP (DT the) (JJ hypothalamic) (NN melanocortin) (NN system))) (PP (IN in) (NP (NN _PROT_) (NN action))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ intracerebroventricular)) (PRN (-LRB- -LRB-) (NP (NN i.c.v.)) (-RRB- -RRB-))) (NN injection)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN with) (CC or) (PP (IN without) (NP (NP (NN SHU9119)) (, ,) (NP (NP (DT a) (JJ potent) (NN antagonist)) (PP (IN of) (NP (JJ alpha-melanocyte) (NN stimulating) (NN hormone)))) (, ,)))))) (PP (IN on) (NP (NP (NP (NN food) (NN intake)) (, ,) (NP (NN body) (NN weight)) (, ,) (CC and) (NP (NP (JJ mitochondrial) (VBG _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN UCP-1)) (-RRB- -RRB-))) (NP (NN mRNA) (NN expression))) (PP (IN in) (NP (NP (DT the) (JJ brown) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNS rats))))))))))
+1 #(S1 (S (NP (NP (DT A) (JJ single) (NN i.c.v.) (NN injection)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBD decreased) (NP (NP (JJ cumulative) (NN food) (NN intake)) (CC and) (NP (NN body) (NN weight) (NN gain)) (, ,) (CC and) (NP (VBN increased) (NN _PROT2_) (NN mRNA) (NN expression))) (PP (IN during) (NP (CD 3) (NN h))) (PP (IN at) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT the) (NN dark) (NN phase))))))))
+1 #(S1 (S (NP (NP (NN Co-injection)) (PP (IN of) (NP (NN SHU9119)))) (ADVP (RB also)) (VP (VBD inhibited) (ADVP (RB completely)) (NP (NP (DT the) (JJ _PROT1_) (NN increase)) (PP (IN in) (NP (NN _PROT2_) (NN mRNA) (NN expression))) (PP (IN in) (NP (DT the) (NN BAT)))))))
+1 #(S1 (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN established) (SBAR (IN that) (S (NP (NP (JJ _PROT1_) (NN beta) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NN AbetaP)) (-RRB- -RRB-))) (VP (VBZ activates) (NP (NP (NP (NN phospholipase) (NN A2)) (, ,) (NP (NN _PROT2_) (NN _PROT2_)) (CC and) (NP (NN phospholipase) (NN D))) (PP (IN of) (NP (NP (NN LA-N-2) (NNS cells)) (CC and) (NP (JJ other) (NN cell) (NNS types)))))))))))))
+1 #(S1 (S (NP (-LRB- -LRB-) (TO -) (-RRB- -RRB-) (NN Nicotine)) (VP (VBD did) (RB not) (VP (VB blunt) (NP (NP (DT the) (NN _PROT1_) (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_))))))))
+1 #(S1 (S (S (NP (NP (DT The) (JJ specific) (NN _PROT1_) (NN _PROT1_) (NN _PROT1_) (-LRB- -LRB-) (NN PKC) (-RRB- -RRB-) (NN inhibitor) (NN chelerythrine)) (PRN (-LRB- -LRB-) (NP (CD 5) (NNS micrometers)) (-RRB- -RRB-))) (VP (VBD inhibited) (NP (NP (NN PTH-)) (, ,) (NP (NN _PROT2_)) (, ,) (NP (NN PGE2-)) (, ,) (CC and) (NP (JJ adenosine-stimulated) (NN Ca2+) (NN reabsorption))) (PP (IN by) (NP (NP (CD 77) (NN %)) (, ,) (NP (CD 67) (NN %)) (, ,) (NP (CD 79) (NN %)) (, ,) (CC and) (NP (CD 100) (NN %)))))) (, ,) (RB respectively)))
+1 #(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (NN PTH)) (, ,) (NP (NN _PROT1_)) (, ,) (NP (NN PGE2)) (, ,) (CC and) (NP (NN adenosine))) (VP (VBP stimulate) (NP (NN Ca2+) (NN reabsorption)) (PP (IN via) (NP (NP (DT a) (NN pathway)) (SBAR (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ independent) (PP (IN of) (NP (NN cAMP))))))) (CC and) (SBAR (WHNP (WDT that)) (S (VP (VBZ involves) (NP (DT a) (ADJP (NN phorbol) (JJ ester-insensitive)) (NN _PROT2_) (NN isotype)))))))))))))
-1 #(S1 (S (NP (DT The) (NNS experiments)) (VP (VBD were) (VP (VBN concluded) (PP (IN by) (S (VP (VBG taking) (NP (NP (NP (NN blood) (NNS samples)) (PP (IN for) (NP (NP (JJ later) (NN analysis)) (PP (IN of) (NP (NN plasma) (NN glucose)))))) (CC and) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (DT the) (JJ following) (NNS hormones)) (: :) (NP (NP (NN _PROT1_)) (, ,) (NP (NN gastrin)) (, ,) (NP (NN CCK)) (, ,) (NP (NN glucagon)) (, ,) (NP (NN somatostatin)) (, ,) (NP (NN _PROT2_)) (CC and) (NP (NN corticosterone))))))))))))))
-1 #(S1 (S (S (NP (DT The) (JJ low-performing) (NN Stock) (NN B) (NNS animals)) (VP (VBD were) (VP (VBN characterized) (PP (IN by) (S (NP (NN [1) (-RRB- -RSB-)) (VP (VBG being) (ADJP (RBR more) (JJ reactive) (PP (TO to) (NP (JJ sensory) (NN stimulation)))))))))) (: :) (NP (NP (JJR higher) (NN startle) (NN amplitude)) (CC and) (NP (JJR shorter) (NN startle) (NN latency))) (: ;) (NP (NP (NP (CD [2) (-RRB- -RSB-)) (VP (VBG having) (NP (NP (NP (JJR higher) (NN plasma) (NN _PROT1_)) (CC and) (NP (NN corticosterone))) (NNS levels)) (, ,) (SBAR (IN whereas) (S (NP (NP (NN plasma) (NN gastrin)) (CC and) (NP (NN _PROT2_))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN lowered))))))) (CC and) (NP (NP (DT a) (JJ strong) (NN tendency)) (PP (IN for) (NP (NP (DT a) (NN decrease)) (PP (ADVP (RB also)) (IN in) (NP (NN plasma) (NN CCK)))))))))
-1 #(S1 (S (S (NP (NP (NN Overexpression)) (PP (IN of) (NP (NP (NN G11alpha)) (CC and) (NP (NP (NNS isoforms)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_)))))) (PP (IN in) (NP (NN islet) (NNS beta-cells)))) (VP (VBZ reveals) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (NP (NN correlation)) (PP (IN between) (NP (NP (NN inositol) (NN phosphate) (NN accumulation)) (CC and) (NP (NN _PROT2_) (NN secretion))))))))) (. .)))
+1 #(S1 (S (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (NN _PROT1_) (NN secretion)) (PP (IN from) (NP (JJ pancreatic) (NNS islets)))) (VP (MD may) (VP (VB be) (VP (VBN mediated) (PP (IN in) (NP (NN part))) (PP (IN by) (NP (NP (NN activation)) (PP (IN of) (NP (NNS _PROT2_) (NP (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PLCs)) (-RRB- -RRB-))) (CC and) (NP (JJ phosphoinositide) (NN hydrolysis)))))))))))))))) (. .)))
+1 #(S1 (S (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (ADJP (RB relatively) (JJ modest)) (JJ fuel-stimulated) (NN _PROT1_) (NN secretion) (NNS responses)) (PP (IN of) (NP (JJ rodent) (NN beta-cell) (NNS lines)))) (VP (MD might) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP (NP (JJ inadequate) (NP (NN expression)) (CC or) (NP (NN activation))) (PP (IN of) (NP (NN _PROT2_) (NNS isoforms))))))))))))))) (. .)))
-1 #(S1 (S (S (NP (NP (JJ Adenovirus-mediated) (NN overexpression)) (PP (IN of) (NP (NP (NN _PROT1_)) (, ,) (NP (NN -beta1)) (, ,) (CC or) (NP (NN -beta3)))) (PP (IN in) (NP (NN INS-1) (CC or) (NN betaG) (NN 40/110) (NNS cells)))) (VP (VBZ results) (PP (IN in) (NP (NP (ADJP (JJ little))) (CC or) (NP (NP (DT no) (NN enhancement)) (PP (IN in) (NP (NP (JJ inositol) (NN phosphate) (-LRB- -LRB-) (NN IP) (-RRB- -RRB-) (NN accumulation)) (CC and) (NP (NP (DT no) (NN improvement)) (PP (IN in) (NP (NN _PROT2_) (NN secretion))))))))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNS cells)) (VP (VBP are) (VP (VBN stimulated) (PP (IN with) (NP (NP (NN glucose)) (CC or) (NP (NN carbachol)))))))) (, ,) (PP (IN despite) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (DT the) (VBN overexpressed) (NNS proteins)) (VP (VBP are) (ADJP (RB fully) (JJ active) (PP (IN in) (NP (NN cell) (NNS extracts))))))))))) (. .)))
-1 #(S1 (S (S (NP (NP (NN Overexpression)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC or) (NP (NN -beta3)))) (PP (IN in) (NP (JJ normal) (NN rat) (NNS islets)))) (VP (VP (VBZ elicits) (NP (NP (DT a) (JJR larger) (NN increase)) (PP (IN in) (NP (NN IP) (NN accumulation))))) (CC but) (, ,) (ADVP (RB again)) (, ,) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN _PROT2_) (NN secretion)))))) (. .)))
-1 #(S1 (S (S (SBAR (IN Because) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN carbachol))) (PP (IN on) (NP (NN _PROT1_) (NN secretion)))) (VP (VBZ is) (VP (VBN thought) (S (VP (TO to) (VP (VB be) (VP (VBN mediated) (PP (IN through) (NP (NP (JJ muscarinic) (NNS receptors)) (SBAR (WHNP (WDT that)) (S (VP (VBP link) (PP (TO to) (NP (NP (DT the) (NN Gq/11) (NN class)) (PP (IN of) (NP (JJ heterotrimeric) (NN G) (NNS proteins)))))))))))))))))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD overexpressed) (NP (NP (NN G11alpha)) (PP (IN in) (NP (NN INS-1) (NNS cells))) (, ,) (UCP (CC either) (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN concert)) (PP (IN with) (NP (NP (NN overexpression)) (PP (IN of) (NP (NP (NN _PROT2_)) (CC or) (NP (NN -beta3)))))))))))) (. .)))
-1 #(S1 (S (S (S (NP (NP (NN Overexpression)) (PP (IN of) (NP (NN G11alpha)))) (VP (VBZ enhances) (NP (NP (NN IP) (NN accumulation)) (, ,) (NP (NP (DT an) (NN effect)) (VP (ADVP (RB slightly)) (VBN potentiated) (PP (IN by) (NP (NP (NN co-overexpression)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC or) (NP (NN -beta3))))))))))) (, ,) (CC but) (S (NP (DT these) (NNS maneuvers)) (VP (VBP do) (RB not) (VP (VB affect) (NP (NP (NN glucose)) (CC or) (NP (JJ carbachol-stimulated) (NN _PROT2_) (NN secretion))))))) (. .)))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT1_)) (CC and) (NP (NN _PROT2_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT1_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT2_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT1_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT2_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT1_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT2_) (CC and) (NN _PROT_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT1_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT2_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT1_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT2_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT1_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT2_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT1_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT2_) (CC and) (NN _PROT_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT1_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT2_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT1_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT2_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT1_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT2_) (CC and) (NN _PROT_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT1_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT2_) (NNS levels)))))))))
+1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT2_) (CC and) (NN _PROT_) (NNS levels)))))))))
+1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT_) (CC and) (NN _PROT2_) (NNS levels)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT_))))) (VP (VBD were) (VP (VBN up-regulated) (PP (IN by) (NP (NP (CD 3.2-)) (CC and) (NP (JJ 1.5-fold)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ late) (NN stage)) (PP (IN of) (NP (NN pregnancy))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (VBD WAT) (NN _PROT_) (NN mRNA) (NN expression)))))))))) (CC and) (S (NP (NP (JJ exogenous) (NN administration)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN uterine) (NN _PROT1_) (CC and) (NN _PROT2_) (NNS levels)))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NP (NN _PROT1_) (NN gene) (NNS expressions)) (PP (IN during) (NP (NN pregnancy)))) (VP (VBP are) (VP (VBN regulated) (ADVP (RB tissue-dependently))))) (, ,) (CC and) (S (NP (NP (NN up-regulation)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT2_)) (CC and) (NP (NN _PROT_) (NN mRNA))))) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (VBN increased) (NN _PROT_) (NNS levels))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NP (NN _PROT1_) (NN gene) (NNS expressions)) (PP (IN during) (NP (NN pregnancy)))) (VP (VBP are) (VP (VBN regulated) (ADVP (RB tissue-dependently))))) (, ,) (CC and) (S (NP (NP (NN up-regulation)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT2_) (NN mRNA))))) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (VBN increased) (NN _PROT_) (NNS levels))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NP (NN _PROT1_) (NN gene) (NNS expressions)) (PP (IN during) (NP (NN pregnancy)))) (VP (VBP are) (VP (VBN regulated) (ADVP (RB tissue-dependently))))) (, ,) (CC and) (S (NP (NP (NN up-regulation)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT_) (NN mRNA))))) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (VBN increased) (NN _PROT2_) (NNS levels))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NP (NN _PROT_) (NN gene) (NNS expressions)) (PP (IN during) (NP (NN pregnancy)))) (VP (VBP are) (VP (VBN regulated) (ADVP (RB tissue-dependently))))) (, ,) (CC and) (S (NP (NP (NN up-regulation)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT1_)) (CC and) (NP (NN _PROT2_) (NN mRNA))))) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (VBN increased) (NN _PROT_) (NNS levels))))))))))))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NP (NN _PROT_) (NN gene) (NNS expressions)) (PP (IN during) (NP (NN pregnancy)))) (VP (VBP are) (VP (VBN regulated) (ADVP (RB tissue-dependently))))) (, ,) (CC and) (S (NP (NP (NN up-regulation)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT1_)) (CC and) (NP (NN _PROT_) (NN mRNA))))) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (VBN increased) (NN _PROT2_) (NNS levels))))))))))))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NP (NN _PROT_) (NN gene) (NNS expressions)) (PP (IN during) (NP (NN pregnancy)))) (VP (VBP are) (VP (VBN regulated) (ADVP (RB tissue-dependently))))) (, ,) (CC and) (S (NP (NP (NN up-regulation)) (PP (IN of) (NP (NP (NN uterine) (NN _PROT_)) (CC and) (NP (NN _PROT1_) (NN mRNA))))) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (VBN increased) (NN _PROT2_) (NNS levels))))))))))))
+1 #(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (VBN isolated) (JJ white) (NNS adipocytes))) (, ,) (NP (DT the) (VBN released) (NN adenosine)) (VP (VBZ acts) (PP (IN as) (NP (DT a) (NP (NN helper)) (CC and/or) (NP (NP (DT a) (JJ positive) (NN regulator)) (PP (IN for) (NP (NN _PROT1_))) (PP (IN in) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NN leptin)))))))) (PP (IN via) (NP (NP (DT an) (NN activation)) (PP (IN of) (NP (NP (NN adenosine) (NN A1) (NNS receptors)) (SBAR (WHNP (WDT that)) (S (VP (VBZ involves) (NP (DT the) (JJ _PROT2_) (NN pathway)))))))))))))) (. .)))
+1 #(S1 (S (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN AVP)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ lysophosphatidic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN LPA)) (-RRB- -RRB-)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB stimulate) (NP (NP (NP (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (CC and) (NP (JJ mitogen-activated) (NN protein) (-LRB- -LRB-) (NN MAP) (-RRB- -RRB-) (NNS kinases))) (CC and) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (JJ vascular) (JJ smooth) (NN muscle) (NNS cells)))))))))))))
+1 #(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ _PROT1_) (NN activation)) (PP (IN of) (NP (NP (NN RSK2)) (, ,) (NP (NP (DT a) (JJ downstream) (NN substrate)) (PP (IN of) (NP (NP (NN ERK1)) (CC and) (NP (NN ERK2))))) (, ,)))) (VP (VBD was) (UCP (ADJP (JJ _PROT2_)) (CC and) (NP (NN PI) (NN 3-kinase-independent))))))
+1 #(S1 (S (NP (NN _PROT1_)) (VP (VBD was) (ADJP (JJ necessary)) (PP (PP (IN in) (NP (NN _PROT2_))) (CC but) (PP (RB not) (IN in) (NP (NP (JJ LPA-induced) (NN activation)) (PP (IN of) (NP (NN p70) (NN S6K)))))))))
+1 #(S1 (S (NP (NP (NN _PROT1_) (JJ central) (NNS injections)) (PP (TO to) (NP (JJ intact) (NNS animals)))) (VP (VBD stimulated) (NP (NP (NN _PROT2_) (NN synthesis)) (CC and) (NP (NN secretion))) (PP (IN without) (S (VP (VBG changing) (PP (IN of) (NP (NNS islets) (NN area)))))))))
+1 #(S1 (S (ADVP (RB Thus)) (, ,) (S (S (NP (NN _PROT1_) (NN administration)) (VP (VBZ stimulates) (NP (NP (NP (NN _PROT2_) (NN synthesis)) (CC and) (NP (NN secretion))) (PP (IN in) (NP (ADJP (ADJP (JJ intact)) (CC and) (ADJP (JJ diabetic))) (NNS animals)))))) (CC and) (S (NP (DT this) (NN effect)) (VP (VBZ is) (ADVP (RBR more)) (VP (VBN expressed) (PP (IN with) (NP (JJ central) (NNS injections)))))))))
-1 #(S1 (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (SBAR (IN that) (S (NP (NP (NN adiposity)) (CC and) (NP (NN serum) (NN _PROT1_) (NNS levels))) (VP (VBP increase) (PP (IN with) (NP (NN age))) (PP (IN in) (NP (JJ male) (NN F-344xBN) (NNS rats)))))) (CC and) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ physiological) (NNS levels)) (PP (IN of) (NP (NN serum) (NN _PROT2_)))) (VP (VBP are) (VP (VBN manipulated) (PP (IN by) (NP (NN fasting))))))) (, ,) (S (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ corresponding) (JJ reciprocal) (NN change)) (PP (IN in) (NP (NP (NP (JJ hypothalamic) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (NN mRNA))) (PP (IN in) (NP (JJ young) (NNS rats)))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (JJR older) (NNS rats)))))))))))))
-1 #(S1 (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (SBAR (IN that) (S (NP (NP (NN adiposity)) (CC and) (NP (NN serum) (NN _PROT1_) (NNS levels))) (VP (VBP increase) (PP (IN with) (NP (NN age))) (PP (IN in) (NP (JJ male) (NN F-344xBN) (NNS rats)))))) (CC and) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ physiological) (NNS levels)) (PP (IN of) (NP (NN serum) (NN _PROT_)))) (VP (VBP are) (VP (VBN manipulated) (PP (IN by) (NP (NN fasting))))))) (, ,) (S (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ corresponding) (JJ reciprocal) (NN change)) (PP (IN in) (NP (NP (NP (JJ hypothalamic) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (NN mRNA))) (PP (IN in) (NP (JJ young) (NNS rats)))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (JJR older) (NNS rats)))))))))))))
-1 #(S1 (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (SBAR (IN that) (S (NP (NP (NN adiposity)) (CC and) (NP (NN serum) (NN _PROT_) (NNS levels))) (VP (VBP increase) (PP (IN with) (NP (NN age))) (PP (IN in) (NP (JJ male) (NN F-344xBN) (NNS rats)))))) (CC and) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ physiological) (NNS levels)) (PP (IN of) (NP (NN serum) (NN _PROT1_)))) (VP (VBP are) (VP (VBN manipulated) (PP (IN by) (NP (NN fasting))))))) (, ,) (S (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ corresponding) (JJ reciprocal) (NN change)) (PP (IN in) (NP (NP (NP (JJ hypothalamic) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (NN mRNA))) (PP (IN in) (NP (JJ young) (NNS rats)))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (JJR older) (NNS rats)))))))))))))
+1 #(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ hypothalamic) (NN _PROT1_) (NN mRNA))) (PP (IN by) (NP (NN _PROT2_)))) (VP (MD may) (VP (VB be) (VP (VBN impaired) (PP (IN with) (NP (NN age)))))))))))
-1 #(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (NP (JJ daily) (NN food) (NN consumption)) (, ,) (NP (NN body) (NN weight)) (, ,) (NP (NN whole-body) (NN oxygen) (NN consumption)) (, ,) (NP (NN serum) (NN _PROT1_)) (, ,) (CC and) (NP (NN _PROT2_) (NN mRNA))) (PP (IN in) (NP (DT the) (NN hypothalamus)))))))
+1 #(S1 (S (S (NP (NN _PROT1_) (NN infusion)) (VP (VBD diminished) (NP (JJ hypothalamic) (NN _PROT2_) (NNS levels)) (PP (IN by) (NP (QP (RB nearly) (CD 50)) (NN %))) (PP (VBN compared) (PP (IN with) (NP (JJ pair-fed) (JJ young) (NNS rats)))))) (, ,) (IN whereas) (S (NP (EX there)) (VP (VBD were) (NP (DT no) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ hypothalamic) (NN _PROT_) (NN mRNA) (NNS levels)) (PP (IN in) (NP (JJ senescent) (NNS rats)))))))))
-1 #(S1 (S (S (NP (NN _PROT1_) (NN infusion)) (VP (VBD diminished) (NP (JJ hypothalamic) (NN _PROT_) (NNS levels)) (PP (IN by) (NP (QP (RB nearly) (CD 50)) (NN %))) (PP (VBN compared) (PP (IN with) (NP (JJ pair-fed) (JJ young) (NNS rats)))))) (, ,) (IN whereas) (S (NP (EX there)) (VP (VBD were) (NP (DT no) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ hypothalamic) (NN _PROT2_) (NN mRNA) (NNS levels)) (PP (IN in) (NP (JJ senescent) (NNS rats)))))))))
-1 #(S1 (S (S (NP (NN _PROT_) (NN infusion)) (VP (VBD diminished) (NP (JJ hypothalamic) (NN _PROT1_) (NNS levels)) (PP (IN by) (NP (QP (RB nearly) (CD 50)) (NN %))) (PP (VBN compared) (PP (IN with) (NP (JJ pair-fed) (JJ young) (NNS rats)))))) (, ,) (IN whereas) (S (NP (EX there)) (VP (VBD were) (NP (DT no) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ hypothalamic) (NN _PROT2_) (NN mRNA) (NNS levels)) (PP (IN in) (NP (JJ senescent) (NNS rats)))))))))
-1 #(S1 (S (NP (NP (DT These) (VBN diminished) (NNS responses)) (PP (TO to) (NP (NN _PROT1_)))) (VP (VP (VBD were) (VP (VBN associated) (PP (IN with)))) (CC and) (VP (MD may) (VP (VB be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (DT an) (JJ impaired) (NN suppression)) (PP (IN of) (NP (JJ hypothalamic) (NN _PROT2_) (NN mRNA) (NNS levels)))))))))))
-1 #(S1 (S (NP (DT The) (NN _PROT1_) (NN _PROT1_) (NN _PROT1_) (JJ specific) (NN inhibitor) (CD Go-6983)) (ADVP (RB further)) (VP (VBD enhanced) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN VACM-1))) (PP (IN on) (NP (JJ _PROT2_) (NN cAMP) (NN production)))))))
+1 #(S1 (S (NP (NP (NN Involvement)) (PP (IN of) (NP (NN thyroid) (NNS hormones))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ intracerebroventricular) (NN _PROT1_) (NN infusion))) (PP (IN on) (NP (NP (NN _PROT2_) (NN _PROT2_) (NN expression)) (PP (IN in) (NP (NN rat) (NN muscle))))))))))
+1 #(S1 (S (NP (NP (DT A) (NN reduction)) (PP (IN of) (NP (NN food) (NN intake))) (VP (VBN imposed) (PP (IN on) (NP (NP (NP (JJ control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NN pair-feeding)) (-RRB- -RRB-))) (, ,) (VP (VBN aimed) (PP (IN at) (S (VP (VBG mimicking) (NP (JJ _PROT1_) (NN hyperphagia)))))) (, ,))))) (VP (VBD produced) (NP (NP (DT a) (JJ marked) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN muscle) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN UCP-3)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN ICV) (NN infusion)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD prevented) (NP (NP (PDT such) (DT a) (NN decrease)) (PP (IN in) (NP (NN _PROT_))))))))))
-1 #(S1 (S (NP (NP (DT A) (NN reduction)) (PP (IN of) (NP (NN food) (NN intake))) (VP (VBN imposed) (PP (IN on) (NP (NP (NP (JJ control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NN pair-feeding)) (-RRB- -RRB-))) (, ,) (VP (VBN aimed) (PP (IN at) (S (VP (VBG mimicking) (NP (JJ _PROT1_) (NN hyperphagia)))))) (, ,))))) (VP (VBD produced) (NP (NP (DT a) (JJ marked) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN muscle) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN UCP-3)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN ICV) (NN infusion)) (PP (IN of) (NP (NN _PROT2_)))) (VP (VBD prevented) (NP (NP (PDT such) (DT a) (NN decrease)) (PP (IN in) (NP (NN _PROT_))))))))))
-1 #(S1 (S (NP (NP (DT A) (NN reduction)) (PP (IN of) (NP (NN food) (NN intake))) (VP (VBN imposed) (PP (IN on) (NP (NP (NP (JJ control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NN pair-feeding)) (-RRB- -RRB-))) (, ,) (VP (VBN aimed) (PP (IN at) (S (VP (VBG mimicking) (NP (JJ _PROT1_) (NN hyperphagia)))))) (, ,))))) (VP (VBD produced) (NP (NP (DT a) (JJ marked) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN muscle) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN UCP-3)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN ICV) (NN infusion)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD prevented) (NP (NP (PDT such) (DT a) (NN decrease)) (PP (IN in) (NP (NN _PROT2_))))))))))
-1 #(S1 (S (NP (NP (DT A) (NN reduction)) (PP (IN of) (NP (NN food) (NN intake))) (VP (VBN imposed) (PP (IN on) (NP (NP (NP (JJ control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NN pair-feeding)) (-RRB- -RRB-))) (, ,) (VP (VBN aimed) (PP (IN at) (S (VP (VBG mimicking) (NP (JJ _PROT_) (NN hyperphagia)))))) (, ,))))) (VP (VBD produced) (NP (NP (DT a) (JJ marked) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN muscle) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN UCP-3)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN ICV) (NN infusion)) (PP (IN of) (NP (NN _PROT2_)))) (VP (VBD prevented) (NP (NP (PDT such) (DT a) (NN decrease)) (PP (IN in) (NP (NN _PROT_))))))))))
-1 #(S1 (S (NP (NP (DT A) (NN reduction)) (PP (IN of) (NP (NN food) (NN intake))) (VP (VBN imposed) (PP (IN on) (NP (NP (NP (JJ control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NN pair-feeding)) (-RRB- -RRB-))) (, ,) (VP (VBN aimed) (PP (IN at) (S (VP (VBG mimicking) (NP (JJ _PROT_) (NN hyperphagia)))))) (, ,))))) (VP (VBD produced) (NP (NP (DT a) (JJ marked) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN muscle) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN UCP-3)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN ICV) (NN infusion)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBD prevented) (NP (NP (PDT such) (DT a) (NN decrease)) (PP (IN in) (NP (NN _PROT2_))))))))))
+1 #(S1 (S (NP (NP (DT A) (NN reduction)) (PP (IN of) (NP (NN food) (NN intake))) (VP (VBN imposed) (PP (IN on) (NP (NP (NP (JJ control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NN pair-feeding)) (-RRB- -RRB-))) (, ,) (VP (VBN aimed) (PP (IN at) (S (VP (VBG mimicking) (NP (JJ _PROT_) (NN hyperphagia)))))) (, ,))))) (VP (VBD produced) (NP (NP (DT a) (JJ marked) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN muscle) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN UCP-3)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN ICV) (NN infusion)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBD prevented) (NP (NP (PDT such) (DT a) (NN decrease)) (PP (IN in) (NP (NN _PROT2_))))))))))
+1 #(S1 (S (S (VP (TO To) (ADVP (RB further)) (VP (VB substantiate) (NP (NP (DT an) (NN involvement)) (PP (IN of) (NP (NN thyroid) (NNS hormones))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN on) (NP (NN muscle) (NN _PROT2_) (NN expression))))))))) (, ,) (S (NP (JJ hypothyroid) (NNS rats)) (VP (VBD were) (ADVP (RB ICV)) (VP (VBN infused) (PP (IN with) (NP (NP (NN _PROT_)) (CC or) (NP (NN vehicle)))))))))
-1 #(S1 (S (S (VP (TO To) (ADVP (RB further)) (VP (VB substantiate) (NP (NP (DT an) (NN involvement)) (PP (IN of) (NP (NN thyroid) (NNS hormones))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN on) (NP (NN muscle) (NN _PROT_) (NN expression))))))))) (, ,) (S (NP (JJ hypothyroid) (NNS rats)) (VP (VBD were) (ADVP (RB ICV)) (VP (VBN infused) (PP (IN with) (NP (NP (NN _PROT2_)) (CC or) (NP (NN vehicle)))))))))
-1 #(S1 (S (S (VP (TO To) (ADVP (RB further)) (VP (VB substantiate) (NP (NP (DT an) (NN involvement)) (PP (IN of) (NP (NN thyroid) (NNS hormones))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN _PROT_))) (PP (IN on) (NP (NN muscle) (NN _PROT1_) (NN expression))))))))) (, ,) (S (NP (JJ hypothyroid) (NNS rats)) (VP (VBD were) (ADVP (RB ICV)) (VP (VBN infused) (PP (IN with) (NP (NP (NN _PROT2_)) (CC or) (NP (NN vehicle)))))))))
+1 #(S1 (S (NP (PRP It)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (PP (IN in) (NP (JJ hypothyroid) (NNS rats))) (, ,) (NP (NN ICV) (NN _PROT1_)) (VP (VBD was) (ADJP (JJ unable) (S (VP (TO to) (VP (VB maintain) (NP (NN muscle) (NN _PROT2_) (NN expression)) (PP (IN at) (NP (NP (NNS values)) (VP (VBN measured) (PP (IN in) (NP (ADJP (NN ad) (NN libitum) (JJ fed)) (NNS controls)))))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (JJ central) (NN _PROT1_)) (VP (VBZ stimulates) (NP (NN T3) (NN production)) (PP (IN via) (NP (NP (DT an) (NN activation)) (PP (IN of) (NP (NN T4))) (PP (TO to) (NP (NN T3) (NN conversion)))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (DT this) (NN stimulation)) (VP (MD could) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN _PROT2_))) (PP (IN on) (NP (NN muscle) (NN _PROT_) (NN expression))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (JJ central) (NN _PROT1_)) (VP (VBZ stimulates) (NP (NN T3) (NN production)) (PP (IN via) (NP (NP (DT an) (NN activation)) (PP (IN of) (NP (NN T4))) (PP (TO to) (NP (NN T3) (NN conversion)))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (DT this) (NN stimulation)) (VP (MD could) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN _PROT_))) (PP (IN on) (NP (NN muscle) (NN _PROT2_) (NN expression))))))))))))))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (JJ central) (NN _PROT_)) (VP (VBZ stimulates) (NP (NN T3) (NN production)) (PP (IN via) (NP (NP (DT an) (NN activation)) (PP (IN of) (NP (NN T4))) (PP (TO to) (NP (NN T3) (NN conversion)))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (DT this) (NN stimulation)) (VP (MD could) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN on) (NP (NN muscle) (NN _PROT2_) (NN expression))))))))))))))
+1 #(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN in) (NP (JJ adult) (NNS rats)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (VP (VBN exerted) (PP (IN at) (NP (JJ hypothalamic) (NN level))) (PP (IN by) (S (VP (VBG regulating) (NP (NP (NP (NP (NN growth) (NN hormone) (VBG releasing) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN GHRH)) (-RRB- -RRB-))) (, ,) (NP (NN somatostatin)) (CC and) (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-)))) (VP (VBG -producing) (NP (NNS neurones))))))))))))))
-1 #(S1 (S (NP (NP (NP (NN _PROT1_) (NN secretion)) (, ,) (NP (NN inositol) (NN phosphate) (NNS levels)) (, ,) (CC and) (NP (NN _PROT2_) (NN _PROT2_) (NNS isozymes))) (PP (IN in) (NP (JJ rodent) (JJ pancreatic) (NNS islets))))))
+1 #(S1 (S (NP (DT These) (NNS findings)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NN concept)) (SBAR (IN that) (S (NP (NP (DT the) (NN underexpression)) (PP (IN of) (NP (DT the) (JJ nutrient-activated) (NN _PROT1_) (NN isozyme)))) (VP (MD may) (VP (VB account) (PP (IN for) (NP (NP (NP (DT the) (JJ minimal) (NN inositol) (NN phosphate)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (CC and) (NP (NN second-phase) (NN _PROT2_) (JJ secretory) (NN response)))) (PP (IN from) (NP (NN mouse) (NNS islets)))))))))))))
+1 #(S1 (S (S (NP (NN Gibbestatin) (NN B)) (VP (VBZ inhibits) (NP (NP (DT the) (JJ _PROT1_) (NN expression)) (PP (IN of) (NP (NN _PROT2_) (NN expression))) (PP (IN in) (NP (JJ cereal) (NN seeds) (NN [In) (NN Process)))))) (S (NP (NNP Citation)) (-RRB- -RSB-))))
+1 #(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN in) (NP (NP (JJ aleurone) (NNS layers)) (PP (IN of) (NP (NN barley)))))) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT2_) (CD _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN GA)) (-RRB- -RRB-))))))))))) (. .)))
+1 #(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (NN gibbestatin) (NN B)) (PRN (-LRB- -LRB-) (NP (NN GNB)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN isolated) (PP (IN from) (NP (ADJP (FW Streptomyces) (FW sp.)) (NN C-39))) (PP (IN as) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (DT the) (JJ _PROT1_) (NN expression)) (PP (IN of) (NP (NP (NN _PROT2_)) (PP (IN in) (NP (NP (NN barley)) (CC and) (NP (NN rice)))))))))) (, ,) (PP (IN with) (NP (NP (NN IC50) (NNS values)) (PP (IN of) (NP (QP (CD 125) (CC and) (CD 70)) (NN microM))) (, ,) (ADVP (RB respectively))))))) (. .)))
+1 #(S1 (S (S (NP (NN GNB)) (VP (VBD suppressed) (NP (NP (NN accumulation)) (PP (IN of) (NP (NP (NP (JJ _PROT1_) (NN barley) (NN high-pI) (NN type) (NN B)) (CC and) (NP (NN rice) (NN RAmylA) (NN _PROT2_))) (NNS transcripts)))))) (. .)))
+1 #(S1 (S (S (NP (DT These) (NNS analyses)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN GNB)) (VP (VBZ inhibits) (NP (NP (DT the) (JJ _PROT1_) (NN expression)) (PP (IN of) (NP (NN _PROT2_)))) (PP (PP (IN by) (S (VP (VBG regulating) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS steps)) (VP (VBN involved) (PP (IN in) (NP (NN ABA) (NN signaling)))))))))) (, ,) (CC but) (PP (RB not) (IN by) (S (VP (VBG acting) (PP (IN as) (NP (DT a) (JJ weak) (NN ABA) (NN analog)))))))))))) (. .)))
+1 #(S1 (S (S (NP (NP (NP (NP (JJ _PROT1_) (NN phospholipase) (NN D1)) (CC and) (NP (NN phospholipase) (NN D2))) (NN activity)) (PP (IN in) (NP (JJ human) (JJ embryonic) (NN kidney-293) (NNS cells)))) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (NN _PROT2_) (NN _PROT2_)) (CC and) (NP (NN protein) (NN kinase) (NN Calpha) (NN signalling) (NN cascade)))))) (. .)))
-1 #(S1 (S (S (NP (NP (NN Co-expression)) (PP (IN of) (NP (NN PLD1))) (PP (IN with) (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- _PROT1_) (NP (NN _PROT1_)) (-RRB- _PROT1_))) (NN _PROT1_)))) (VP (VBZ has) (NP (DT the) (JJ same) (NN effect)) (, ,) (SBAR (IN while) (S (NP (NP (NN co-expression)) (PP (IN of) (NP (NN PLD2))) (PP (IN with) (NP (NN _PROT2_)))) (VP (VBZ allows) (NP (NN PLD2) (NN activity)) (S (VP (TO to) (VP (VB be) (VP (VBN stimulated) (PP (IN in) (NP (DT an) (JJ _PROT_) (NN manner)))))))))))) (. .)))
-1 #(S1 (S (S (NP (NP (NN Co-expression)) (PP (IN of) (NP (NN PLD1))) (PP (IN with) (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- _PROT1_) (NP (NN _PROT1_)) (-RRB- _PROT1_))) (NN _PROT1_)))) (VP (VBZ has) (NP (DT the) (JJ same) (NN effect)) (, ,) (SBAR (IN while) (S (NP (NP (NN co-expression)) (PP (IN of) (NP (NN PLD2))) (PP (IN with) (NP (NN _PROT_)))) (VP (VBZ allows) (NP (NN PLD2) (NN activity)) (S (VP (TO to) (VP (VB be) (VP (VBN stimulated) (PP (IN in) (NP (DT an) (JJ _PROT2_) (NN manner)))))))))))) (. .)))
-1 #(S1 (S (S (NP (NP (NN Co-expression)) (PP (IN of) (NP (NN PLD1))) (PP (IN with) (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- _PROT_) (NP (NN _PROT_)) (-RRB- _PROT_))) (NN _PROT_)))) (VP (VBZ has) (NP (DT the) (JJ same) (NN effect)) (, ,) (SBAR (IN while) (S (NP (NP (NN co-expression)) (PP (IN of) (NP (NN PLD2))) (PP (IN with) (NP (NN _PROT1_)))) (VP (VBZ allows) (NP (NN PLD2) (NN activity)) (S (VP (TO to) (VP (VB be) (VP (VBN stimulated) (PP (IN in) (NP (DT an) (JJ _PROT2_) (NN manner)))))))))))) (. .)))
-1 #(S1 (S (S (NP (NP (DT The) (JJ PKC-specific) (NNS inhibitors)) (NP (NP (NN bisindolylmaleimide)) (CC and) (NP (VB Go) (NN 6976)))) (VP (VBP abolish) (NP (JJ _PROT1_) (NN PLD2) (NN activation)) (PP (IN in) (NP (NP (NN HEK-293) (NNS cells)) (VP (VBG co-expressing) (NP (NP (DT the) (NN insulin) (NN receptor)) (, ,) (NP (NP (NN _PROT2_)) (CC and) (NP (NN PLD2))))))) (, ,) (S (VP (VBG confirming) (SBAR (IN that) (S (NP (RB not) (RB only) (NP (NN PLD1)) (, ,) (CC but) (NP (NP (NN PLD2)) (ADVP (RB as) (RB well))) (, ,)) (VP (VBZ is) (VP (VBN regulated) (PP (IN in) (NP (DT a) (JJ PKC-dependent) (NN manner))))))))))) (. .)))
+1 #(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN _PROT1_) (NN treatment)) (VP (VBZ results) (PP (IN in) (NP (NP (NN activation)) (PP (IN of) (NP (CC both) (NP (NN PLD1)) (CC and) (NP (NN PLD2)))) (PP (IN in) (NP (JJ appropriate) (NN cell) (NNS types))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (JJ appropriate) (JJ upstream) (NN intermediate) (NN signalling) (NNS components)) (, ,) (PP (FW i.e.) (NP (NP (NN PKCalpha)) (CC and) (NP (NN _PROT2_)))) (, ,)) (VP (VBP are) (VP (VBN expressed) (PP (IN at) (NP (JJ sufficient) (NNS levels))))))))))) (. .)))
